Patterson posts
FeedPosted Apr 10th 2008 11:05AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Pfizer (PFE)
MOST NOTEWORTHY: Patterson Companies, Virgin Media and MannKind were today's noteworthy downgrades:
- Patterson (NASDAQ:PDCO) was downgraded to Neutral from Outperform at Baird, as the firm's checks indicate industry fundamentals have softened and it sees greater near-term risk for dental consumables than dental equipment.
- Virgin Media (NASDAQ:VMED) was cut to Hold from Buy at Jefferies as they believe the company's results could be under pressure given the continued competitive activity and potential weakening of the UK economy.
- Piper downgraded shares of MannKind (NASDAQ:MNKD) to Neutral from Buy and lowered their target to $1.50 after Pfizer (NYSE:PFE) discontinued inhaled insulin Exubera due to an increase in lung cancer cases.
OTHER DOWNGRADES:
- Lehman cut Cheniere Energy (LNG) to Equal Weight from Overweight.
- Pantry (PTRY) was cut to Market Perform from Outperform at Friedman Billings.
- JP Morgan lowered Watsco (WSO) to Neutral from Overweight.
Posted Dec 8th 2007 8:39AM by Peter Cohan (RSS feed)
Filed under: Johnson and Johnson (JNJ)
Just because a company is in the health are field, it doesn't mean it's a buy. That's because investors have figured out that future demand for a product does not translate into unexpectedly high profit for the companies that meet the demand.
Obviously demand for medical products and services is going to rise as 77 million baby boomers age. But that demand does not necessarily translate into making money -- either in the product or stock markets. Why not? Because the competition is fierce. Not only are rivals going after each other with aggressive marketing but in many cases the government or pharmacy benefit managers are the buyers. And these buyers cap prices -- often at levels that make it difficult for suppliers to make a decent profit.
Furthermore, companies in this industry must invest considerable amounts in R&D to develop new products since they can't rely on profits from products that lose patent protection due to competition from generics. And the success rates of those R&D efforts seem to be dropping -- leaving many competitors with high costs, declining revenues, and uncertain futures.
Continue reading Three health care stocks to avoid: Johnson & Johnson, Medtronic and Patterson
Posted Sep 7th 2007 10:50AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, U.S. Steel (X)
MOST NOTEWORTHY: Patterson-UTI Energy, Nabors Industries, US Steel Group, Cooper Companies and Continental AG were today's noteworthy upgrades:
- Bernstein upgraded Patterson-UTI Energy Inc (NASDAQ: PTEN) and Nabors Industries Limited (NYSE: NBR) to Outperform from Market Perform citing valuations and secular growth trends.
- Citigroup upgraded US Steel Corporation (NYSE: X) to Buy from Hold and raised their target to $118 to reflect operating catalysts and their expectations for domestic steel markets to improve in Q4 and 2008.
- Cooper Companies Inc (NYSE: COO) was also upgraded to Buy from Hold at Citigroup despite the lowered guidance as they believe the company's products are improving and earnings upside is possible.
- WestLB upgraded Continental AG (OTC: CTTAY) to Buy from Hold after the tire marker announced plans to reorganize its company structure into six divisions following the purchase of Siemens AG's (NYSE: SI) VDO automotive unit.
OTHER UPGRADES:
Posted Feb 27th 2007 10:59AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Bad news, Bed Bath and Beyond (BBBY), NYSE Euronext (NYX), Marvell Technology Group (MRVL)
MOST NOTEWORTHY: NYSE Group Inc (NYX), Patterson-UTI Energy (PTEN) and HomeBanc Corp (HMB) were today's more notable downgrades:
- JP Morgan downgraded shares of the NYSE Group Inc (NYSE: NYX) to Underweight from Neural to reflect their belief that the company's float will increase significantly in March due to the acquisition of Euronext and the lockup expiration. JP Morgan believes this could bring selling pressure.
- Credit Suisse downgraded shares of Patterson-UTI Energy (NASDAQ: PTEN) citing negative earnings impact from share losses and industry capacity additions.
- Shares of HomeBanc Corp (NYSE: HMB) were downgraded to Underperform from Market Perform with a $2.60 target at Friedman Billings based on continued losses and an unlikely sale given market conditions.
OTHER DOWNGRADES:
- Wachovia downgraded Hub International Ltd (NYSE: HBG) to Market Perform from Outperform following news of a private-equity acquisition for $40 a share.
- UBS downgraded Bed Bath & Beyond Inc (NASDAQ: BBBY) to Neutral from Buy on valuation.
- Citigroup downgraded Burlington Northern Santa Fe Corp (NYSE: BNI) to Hold from Buy.
- AG Edwards cut Teekay LNG Partners (NYSE: TGP) and Teekay Offshore Partners (NYSE: TOO) to Hold from Buy citing valuation.
- Raymond James downgraded shares of Marvel Entertainment Inc (NYSE: MVL) to Market Perform from Outperform.
- Lazard downgraded Thoratec Corp (NASDAQ: THOR) to Sell from Hold with a $15 target. They recommend selling shares ahead of a likely FDA decision to call an advisory panel for HeartMate II.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).